Risk score based intervention for Iatrogenic Disease

Phase-Based Progress Estimates
Robert Wood Johnson University Hospital Somerset, Somerville, NJ
Iatrogenic Disease+1 More
Risk score based intervention - Other
All Sexes
What conditions do you have?

Study Summary

This study is evaluating whether a medication risk score can be used to identify patients at high risk for readmission.

See full description

Eligible Conditions

  • Iatrogenic Disease
  • Risk Reduction

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether Risk score based intervention will improve 1 primary outcome and 1 secondary outcome in patients with Iatrogenic Disease. Measurement will happen over the course of 30 days after hospital discharge.

Day 30
Number of individuals with an emergency department visit or hospital readmission
At time of intervention
Difference in score between patients aged older and younger than 65 years

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Standard of Care
1 of 2
1 of 2
Active Control
Experimental Treatment

This trial requires 800 total participants across 2 different treatment groups

This trial involves 2 different treatments. Risk Score Based Intervention is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Discharge medication regimen instructions will be provided upon discharge after being assessed using the MWRS, optimized, and assessed by the prescriber.
Standard of CareDischarge medication regimen instructions will be provided upon discharge after being assessed by the prescriber.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at time of intervention
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly at time of intervention for reporting.

Who is running the study

Principal Investigator
L. B. P.
Prof. Luigi Brunetti PharmD,, PhD
Rutgers, The State University of New Jersey

Closest Location

Robert Wood Johnson University Hospital Somerset - Somerville, NJ

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
is required You need to be hospitalized for at least 48 hours. show original
The text says that the patient was prescribed 5 medications at the hospital discharge. show original
identified patients as high-risk The study found that patients who had a baseline medication risk score of 20 or more were considered to be high-risk. show original

Patient Q&A Section

Can risk reduction be cured?

"The present findings are inconsistent with the hypothesis of a causal relationship between alcohol and risk-taking behaviors and with the assumption that changing risk-taking attitudes will lead to lower levels of drinking. In line with other studies, the present findings suggest that changing risk-taking attitudes towards drinking may not be the most efficacious approach to reducing alcohol-related harm." - Anonymous Online Contributor

Unverified Answer

How many people get risk reduction a year in the United States?

"The prevalence of many preventive health actions varied by type of behavioral goal of risk reduction. Interventions aiming to increase uptake and maintenance of a lifestyle change may be particularly effective during midlife or as a means of reducing the risk of adverse cardiac events in women." - Anonymous Online Contributor

Unverified Answer

What causes risk reduction?

"The best way to assess personal risk for a disease is through comprehensive medical record review, consultation with a physician, and use of validated questionnaires." - Anonymous Online Contributor

Unverified Answer

What are common treatments for risk reduction?

"Most individuals who qualify for sex-specific HIV testing are not aware of their risk of contracting the virus, and are not aware of the potential benefits of sex-specific testing. Almost half of the MSM did not seek voluntary risk reduction prior to their HIV testing, and almost one third of them were unaware of the availability of pre-testning HIV prevention and risk reduction services. There are significant benefits of testing, particularly for those MSM who intend to seek additional testing in the future. Those who were not aware of available services, and who were unaware of their risk of infection, can benefit from educational campaigns to better inform them of the importance of HIV testing and risk reduction." - Anonymous Online Contributor

Unverified Answer

What are the signs of risk reduction?

"Risk reduction has its own signs and symptoms when a new product is introduced for use by the public. There are also important and predictable signs and symptoms of risk reduction. In other words, risk reduction is not just cosmetic." - Anonymous Online Contributor

Unverified Answer

What is risk reduction?

"The reduction of heart disease risk in the general population is still one of the major goals for health care policy in developing countries. Data from a recent study presented here show that improving diet may offer an important alternative (or additional resource) in reducing the burden of CHD in developed countries, especially among high-risk subjects." - Anonymous Online Contributor

Unverified Answer

Does risk reduction run in families?

"Given the rarity and heterogeneity of risk alleles across individuals, and the rarity and heterogeneity of risk gene transmission, we argue that genetic predisposition as a whole is primarily a complex polygenic risk, not a simple sum of single deleterious mutations." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for risk reduction?

"It is recommended that patients with risk factors for MS consider clinical trials of anti-inflammatory agents as a first step in risk reduction before initiating treatment." - Anonymous Online Contributor

Unverified Answer

How does risk score based intervention work?

"Results from a recent clinical trial is interesting because it shows that in this low-risk population, a low-dosage intervention can potentially prevent the occurrence of cardiovascular disease. The potential impact of a more effective interventions is to be investigated in future studies." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of risk score based intervention?

"Side effects of interventions are highly variable and often different across trials. A key aim for future research is to develop methods to inform more realistic sample sizes, and also to identify which interventions can be more effective than others." - Anonymous Online Contributor

Unverified Answer

Have there been other clinical trials involving risk score based intervention?

"There are no additional RCTs for people with CVD using risk scores to identify ischemic heart disease. Risk scores are also very few in number and are mostly used for prediction of future cardiovascular events, although this is an important use of risk scores. There is good evidence of risk scores being used for secondary prevention, and with further large clinical trials, their use should expand. However, the evidence for primary interventions is weaker, although further large trials are needed." - Anonymous Online Contributor

Unverified Answer

Has risk score based intervention proven to be more effective than a placebo?

"Patients with low risk of future events showed a better evolution and reduced rate of complications after hospital discharge, suggesting that intervention is needed on those patients." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Iatrogenic Disease by sharing your contact details with the study coordinator.